Ruhong Jiang

Dr. Ruhong Jiang is the Chief Executive Officer of ASC Therapeutics, a biopharmaceutical company specializing in gene therapy and allogeneic cell therapy. Under his leadership, ASC Therapeutics has advanced two programs into clinical stages within just two years, notably focusing on therapies for hemophilia A and graft-versus-host disease.12

Background and Education

Dr. Jiang holds a Bachelor of Science degree in Biology from Fudan University, a Master of Science in Reproductive Biology from China Agricultural University, and a Ph.D. in Genetics from Oklahoma State University. He also completed a postdoctoral fellowship at Baylor College of Medicine.1 His extensive experience includes roles at various biotechnology firms, where he has contributed to pharmacogenetics and molecular genetics projects with significant budgets.12

Professional Experience

Before founding ASC Therapeutics, Dr. Jiang was the General Manager at MicuRx (Shanghai) Pharmaceutical, where he established the company's operations in China. He also led the Pharmacogenetics Program at Stanford Research Institute International and held positions at Boehringer Ingelheim Pharmaceuticals and Genaissance Pharmaceuticals, focusing on biomarker discovery and clinical bioinformatics.12

Achievements

Dr. Jiang has published over 40 articles in the fields of human genetics and pharmacogenetics, demonstrating a strong commitment to advancing personalized medicine and regenerative therapies.1 Under his guidance, ASC Therapeutics has received FDA Fast Track Designation for its AAV8-based gene therapy for hemophilia A, marking significant progress in the treatment of this condition.23

Interests

In addition to his professional pursuits, Dr. Jiang is deeply interested in the ethical and societal implications of personalized medicine and global health initiatives.1